Capital Fund Management (CFM)
BMRN icon

Capital Fund Management (CFM)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Fund Management (CFM)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
235,421
+54,356
+30% +$2.98M 0.06% 470
2026
Q1 		$10.2M Sell
181,065
-35,369
-16% -$2.06M 0.05% 543
2025
Q4 		$12.9M Buy
216,434
+1,813
+0.8% +$98.7K 0.04% 695
2025
Q3 		$11.6M Buy
214,621
+22,834
+12% +$1.31M 0.03% 744
2025
Q2 		$10.5M Buy
191,787
+146,481
+323% +$8.63M 0.03% 725
2025
Q1 		$3.2M Sell
45,306
-13,241
-23% -$891K 0.01% 1221
2024
Q4 		$3.85M Sell
58,547
-92,349
-61% -$6.19M 0.01% 1205
2024
Q3 		$10.6M Buy
150,896
+118,319
+363% +$9.89M 0.03% 695
2024
Q2 		$2.68M Sell
32,577
-7,522
-19% -$626K 0.01% 1248
2024
Q1 		$3.5M Buy
+40,099
New +$3.59M 0.01% 1204
2020
Q1 		– Sell
-8,872
Closed -$750K – 1571
2019
Q4 		$750K Buy
+8,872
New +$670K 0.01% 1228
2017
Q3 		– Sell
-4,635
Closed -$421K – 1525
2017
Q2 		$421K Sell
4,635
-3,446
-43% -$314K ﹤0.01% 1169
2017
Q1 		$709K Buy
+8,081
New +$719K 0.01% 1028
2016
Q3 		– Sell
-98,181
Closed -$7.64M – 1565
2016
Q2 		$7.64M Buy
+98,181
New +$8.35M 0.07% 315
2015
Q4 		– Sell
-137,052
Closed -$14.4M – 1542
2015
Q3 		$14.4M Buy
137,052
+131,298
+2,282% +$17.5M 0.16% 160
2015
Q2 		$787K Buy
+5,754
New +$713K 0.01% 897
2013
Q3 		– Sell
-24,264
Closed -$1.61M – 1582
2013
Q2 		$1.35M Buy
+24,264
New +$1.51M 0.02% 725

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Capital Fund Management (CFM)'s BMRN Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its BioMarin Pharmaceuticals (BMRN) stake by 30% in Q2 2026, buying an estimated $2.98M and bringing the position to 235,421 shares worth $13.5M. The position accounts for 0.06% of the portfolio, ranked #470.

Capital Fund Management (CFM) first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $14.4M in Q3 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Capital Fund Management (CFM) held 235,421 shares of BioMarin Pharmaceuticals worth $13.5M as of Q2 2026.
  • Capital Fund Management (CFM) bought 54,356 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.98M.
  • BioMarin Pharmaceuticals made up 0.06% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #470 holding.
  • Capital Fund Management (CFM) first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Capital Fund Management (CFM)'s BioMarin Pharmaceuticals position peaked at $14.4M in Q3 2015.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.